MedTrace Logo

Golimumab for Adherence in Rheumatoid Arthritis

NCT03729349 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 222

Last updated 2024-07-18

No results posted yet for this study

Summary

The purpose of this study is to determine if non-adherence to Rheumatoid Arthritis (RA) drugs in participants treated with biologic disease modifying anti-rheumatic drugs (DMARDs) is associated with a greater incidence of disease in clinical practice.

Conditions

  • Arthritis, Rheumatoid

Interventions

BIOLOGICAL

Golimumab

Participants will receive golimumab as a part of clinical practice.

Sponsors & Collaborators

  • Janssen Inc.

    lead INDUSTRY

Principal Investigators

  • Janssen Inc. Clinical Trial · Janssen Inc.

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2023-06-19
Completion
2023-06-19

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03729349 on ClinicalTrials.gov